ALMS Alumis Net earnings per share for the last 12 months

ALMS (Alumis Inc) - company brandmark

Alumis Inc. (ALMS) develops IT platforms and anti-inflammatory drugs, diversifying its research across various diseases. High barriers to entry and patent protection for its molecules shield the business from new competitors. The company's EPS TTM trend demonstrates a balance between actual earnings and market value, where the value of -3.82 reflects the current figure. Currently, the biotech firm is actively deploying its IPO capital to conduct costly clinical trials.

ALMS Alumis Inc. Earnings per share for the trailing year (06/29/2024 - 11/12/2026)

Alumis Inc - analytical breakdowns and key metrics (ALMS)

- stock price and consensus target price:
Stock Price Alumis Inc.|ALMS - Average Forecast Price
- market capitalization data:
Market Valuation Alumis Inc.|ALMS - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Single Share Alumis|ALMS - Accounting Value of Company|Market Value to Book Value Ratio alumis.com|ALMS - Company Assets
- debt level and financial liquidity data:
Debt to Equity Alumis Inc.|ALMS - Long-Term Debt to Equity|Short-Term Debt to Equity Alumis Corp|ALMS - Company Cumulative Debt|Debts to Book Capitalization Alumis Inc.|ALMS - Long-Term Indebtedness|Company Current Liabilities Alumis|Quick Ratio alumis.com
- earnings and multiples data:
ALMS - Net Profit|Expected Profit Alumis Inc.|ALMS - Price to Earnings Ratio|Projected Price to Earnings Alumis|ALMS - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alumis Inc.|ALMS - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Alumis|ALMS - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months alumis.com|ALMS - Expected net earnings per share growth this year|Expected earnings per share growth for next year Alumis Inc.
Basic company analysis:Alumis Inc. (ALMS)
Mass-produced product of Alumis Corp

This indicator measures the aggregate net income distributed per share over a rolling year, allowing for an assessment of the business's actual value generation efficiency. By analyzing the TTM net income per share on the GURU.Markets platform, an investor separates market noise from the operational resilience of Alumis Inc. (ALMS), weighing financial results against the risks of FDA regulatory restrictions for the TYK2 drug class.

Analysis of competing companies

Jazz Pharmaceuticals - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months cytokinetics.com|PTCT (PTC Therapeutics) - Net earnings per share for the last 12 months|Scholar Rock, Inc. (SRRK) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Centessa Pharmaceuticals PLC|DYN: Earnings per share for the trailing year|Earnings per share for the last twelve months Edgewise Therapeutics (EWTX)|RAPP - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Zevra Therapeutics, Inc. ZVRA|Contineum Therapeutics Inc - Earnings per share for the last twelve months|LRMR - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Capricor Therapeutics|TRDA: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year channeltherapeutics.com PTHS|Net earnings per share for the last 12 months MNOV|Net earnings per one share for the last twelve months Serina Therapeutics Inc SER|Net earnings per share (EPS TTM) BTAI|Net earnings per share (EPS TTM) promisneurosciences.com (PMN)|Earnings per share for the last twelve months Apimeds Pharmaceuticals US APUS|AEON Biopharma Inc. - Earnings per share for the last twelve months|NLSP: Net earnings per share for the last 12 months|BNOX - Net earnings per share (EPS TTM)|FSD Pharma (HUGE) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months Reata Pharma